Gilead's coronavirus drug flops in first major trial
Vials of remdesivir, which is administered intravenously. Photo: Ulrich Perrey/AFP via Getty Images
Remdesivir, the drug made by Gilead Sciences that is being tested on coronavirus patients, "was not associated with clinical or virological benefits," according to a leaked summary of a randomized trial posted by the World Health Organization and viewed by STAT and the Financial Times on Thursday.
Why it matters: Experts have placed a lot of hope in remdesivir as an antiviral treatment for COVID-19, but the preliminary results of this study dash a lot of that hope. However, the study is still undergoing peer review, and Gilead is arguing the results weren't characterized appropriately.